Needham Reiterates Hold on Neurocrine Biosciences
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Neurocrine Biosciences (NASDAQ:NBIX).
October 31, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Neurocrine Biosciences, indicating a neutral stance on the stock.
The reiteration of a Hold rating by Needham suggests that the analyst does not see significant upside or downside in the short term for NBIX. This neutral stance implies that investors may not expect major price movements based on this rating alone.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100